Voloridge Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.2M | Buy |
2,474,075
+440,292
| +22% | +$3.95M | 0.08% | 298 |
|
|
2025
Q1 | $15.3M | Buy |
2,033,783
+453,823
| +29% | +$3.4M | 0.06% | 434 |
|
|
2024
Q4 | $11.9M | Sell |
1,579,960
-212,948
| -12% | -$1.6M | 0.04% | 526 |
|
|
2024
Q3 | $13.6M | Sell |
1,792,908
-797,953
| -31% | -$6.06M | 0.05% | 483 |
|
|
2024
Q2 | $16M | Buy |
2,590,861
+1,623,139
| +168% | +$10M | 0.06% | 446 |
|
|
2024
Q1 | $4.92M | Sell |
967,722
-113,924
| -11% | -$579K | 0.02% | 665 |
|
|
2023
Q4 | $6.48M | Buy |
1,081,646
+737,798
| +215% | +$4.42M | 0.03% | 566 |
|
|
2023
Q3 | $2.43M | Buy |
343,848
+252,451
| +276% | +$1.79M | 0.01% | 867 |
|
|
2023
Q2 | $643K | Sell |
91,397
-581,868
| -86% | -$4.1M | ﹤0.01% | 1196 |
|
|
2023
Q1 | $5.62M | Buy |
673,265
+408,048
| +154% | +$3.4M | 0.03% | 639 |
|
|
2022
Q4 | $3.04M | Buy |
+265,217
| New | +$3.04M | 0.02% | 844 |
|
|
2022
Q2 | – | Sell |
-127,510
| Closed | -$2.07M | – | 1424 |
|
|
2022
Q1 | $2.07M | Sell |
127,510
-566,320
| -82% | -$9.21M | 0.01% | 936 |
|
|
2021
Q4 | $9.61M | Sell |
693,830
-486,467
| -41% | -$6.74M | 0.05% | 485 |
|
|
2021
Q3 | $17M | Buy |
1,180,297
+607,919
| +106% | +$8.74M | 0.11% | 253 |
|
|
2021
Q2 | $9.05M | Buy |
+572,378
| New | +$9.05M | 0.06% | 439 |
|
|
2021
Q1 | – | Sell |
-1,038,874
| Closed | -$7.74M | – | 1393 |
|
|
2020
Q4 | $7.74M | Buy |
+1,038,874
| New | +$7.74M | 0.06% | 348 |
|
|
2019
Q4 | – | Sell |
-35,646
| Closed | -$102K | – | 1085 |
|
|
2019
Q3 | $102K | Sell |
35,646
-94,654
| -73% | -$271K | ﹤0.01% | 1016 |
|
|
2019
Q2 | $494K | Buy |
130,300
+117,795
| +942% | +$447K | 0.01% | 566 |
|
|
2019
Q1 | $102K | Buy |
+12,505
| New | +$102K | ﹤0.01% | 908 |
|